 |
 Video: What is a Stock Split?
|
|
|
| argenx is a clinical-stage biotechnology company developing differentiated therapies for the treatment of severe autoimmune diseases and cancer. Co. is developing its main product candidate, efgartigimod, for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris and chronic demyelinating polyneuropathy, all of which are severe autoimmune diseases associated with high levels of circulating pathogenic immunoglobulin G antibodies for which there are few biologic treatments and a severe unmet medical need exists. Co. is also developing cusatuzumab in hematological cancer indications, acute myeloid leukemia, as well as high-risk myelodysplastic syndrome. According to our argenx SE stock split history records, argenx SE has had 0 splits. | |
|
argenx SE (ARGX) has 0 splits in our argenx SE stock split history database.
Looking at the argenx SE stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into argenx SE shares, starting with a $10,000 purchase of ARGX, presented on a split-history-adjusted basis factoring in the complete argenx SE stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
05/19/2017 |
|
| End date: |
05/03/2024 |
|
| Start price/share: |
$21.85 |
|
| End price/share: |
$388.20 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
1,676.66% |
|
| Average Annual Total Return: |
51.18% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$177,654.28 |
|
| Years: |
6.96 |
|
|
|
|
|
